Gemcitabine và carboplatin cho bệnh nhân ung thư vú di căn đã điều trị trước đó: giá trị dự đoán của các kiểu phân loại được xác định bằng miễn dịch hóa mô học

Jemal A, Siegel R, Ward E et al (2009) Cancer statistics. CA Cancer J Clin 59:225–249 Bernard-Marty C, Cardoso F, Piccart MJ (2004) Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9:617–632 Hamilton A, Hortobagyi G (2005) Chemotherapy: what progress in the last 5 years? J Clin Oncol 23:1760–1775 Carrick S, Parker S, Thornton CE et al (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 15:CD003372 Mauri D, Polyzos NP, Salanti G et al (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 17:1780–1791 Moreno-Aspitia A, Perez EA (2009) Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 84:533–545 Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1–22 Perez EA (2004) Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 4(Suppl 3):S113–S116 Nasr FL, Chahine GY, Kattan JG et al (2004) Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer 5:117–122 Loesch D, Asmar L, McIntyre K et al (2008) Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer 8:178–186 Laessig D, Stemmler HJ, Vehling-Kaiser U et al (2007) Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology 73:407–414 Brandi M, Vici P, Lopez M et al (2004) Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. Semin Oncol 31:13–19 Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750 Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18–43 Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10 Onitilo AA, Engel JM, Greenlee RT et al (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7:4–13 Wiechmann L, Sampson M, Stempel M et al (2009) Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 16:2705–2710 Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747 Jones RL, Salter J, A’Hern R et al (2009) Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 119:315–323 Jones RL, Salter J, A’Hern R et al (2009) The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 16:53–68 Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168–1176 Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752 Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874 Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685 Pusztai L (2008) Current status of prognostic profiling in breast cancer. Oncologist 13:350–360 de Ronde JJ, Hannemann J, Halfwerk H et al (2009) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119–126 Desmedt C, Haibe-Kains B, Wirapati P et al (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158–5165 Elliott RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23:2078–2093 Thuerigen O, Schneeweiss A, Toedt G et al (2006) Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24:1839–1845 Bai J, Sata N, Nagai H (2007) Gene expression analysis for predicting gemcitabine sensitivity in pancreatic cancer patients. HPB (Oxford) 9:150–155